Jump Financial LLC Has $423,000 Position in Kenvue Inc. $KVUE

Key Points

• Jump Financial LLC reduced its holdings in Kenvue Inc. (KVUE) by 42.8% during the first quarter, now owning 17,653 shares worth $423,000.
• Multiple institutional investors, including Vanguard Group Inc. and JPMorgan Chase & Co., increased their stakes in Kenvue, indicating continued interest in the stock despite recent adjustments to price targets.
• Kenvue recently reported a quarterly EPS of $0.29, which exceeds analysts' expectations, and announced a slight increase in its quarterly dividend, raising it to $0.2075.

Jump Financial LLC lessened its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 42.8% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 17,653 shares of the company's stock after selling 13,226 shares during the period. Jump Financial LLC's holdings in Kenvue were worth $423,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in KVUE. Pittenger & Anderson Inc. acquired a new position in shares of Kenvue during the first quarter valued at $30,000. TruNorth Capital Management LLC acquired a new position in shares of Kenvue during the first quarter valued at $36,000. Clal Insurance Enterprises Holdings Ltd lifted its stake in shares of Kenvue by 378.5% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company's stock valued at $39,000 after acquiring an additional 1,287 shares during the period. Bank Julius Baer & Co. Ltd Zurich lifted its stake in shares of Kenvue by 120.6% during the first quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company's stock valued at $41,000 after acquiring an additional 929 shares during the period. Finally, Continuum Advisory LLC lifted its stake in shares of Kenvue by 2,071.1% during the first quarter. Continuum Advisory LLC now owns 1,954 shares of the company's stock valued at $47,000 after acquiring an additional 1,864 shares during the period. Institutional investors own 97.64% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on KVUE. UBS Group cut their price target on Kenvue from $25.00 to $23.00 and set a "neutral" rating on the stock in a research note on Thursday, July 17th. Zacks Research raised Kenvue to a "strong sell" rating in a research note on Monday, August 11th. Canaccord Genuity Group cut their price target on Kenvue from $29.00 to $26.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Royal Bank Of Canada cut their price target on Kenvue from $24.00 to $22.00 and set a "sector perform" rating on the stock in a research note on Friday, August 8th. Finally, JPMorgan Chase & Co. cut their target price on Kenvue from $27.00 to $26.00 and set an "overweight" rating on the stock in a research note on Friday, July 25th. Five investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $24.38.

Kenvue Trading Up 0.3%

NYSE:KVUE traded up $0.06 during mid-day trading on Thursday, hitting $20.51. The company had a trading volume of 15,322,729 shares, compared to its average volume of 17,232,725. Kenvue Inc. has a fifty-two week low of $19.75 and a fifty-two week high of $25.17. The business's fifty day moving average is $21.42 and its two-hundred day moving average is $22.42. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98. The firm has a market cap of $39.35 billion, a P/E ratio of 27.71, a P/E/G ratio of 2.97 and a beta of 0.83.

Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The firm had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. During the same quarter in the prior year, the firm posted $0.32 earnings per share. The company's quarterly revenue was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were given a dividend of $0.2075 per share. This is an increase from Kenvue's previous quarterly dividend of $0.21. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.0%. The ex-dividend date of this dividend was Wednesday, August 13th. Kenvue's payout ratio is 112.16%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.